SCHEMBL4153897

SCHEMBL4153897

COc1ccc(Cn2c(C#N)c(CCCOc3cccc4ccccc34)c3cccc(-c4ccccc4C)c32)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCL1 Q07820 15/20 0.49
ALB P02768 2/20 0.49
SIRT2 Q8IXJ6 1/20 0.41
HTR1A P08908 1/20 0.40
HTR1D P28221 1/20 0.40
HTR1B P28222 1/20 0.40
CDC7 O00311 2/20 0.39
MARK3 P27448 2/20 0.39
GSK3B P49841 2/20 0.39
IRAK1 P51617 2/20 0.39
NEK4 P51957 2/20 0.39
MAP4K2 Q12851 2/20 0.39
CAMK2B Q13554 2/20 0.39
CDC42BPA Q5VT25 2/20 0.39
MARK2 Q7KZI7 2/20 0.39
TAOK1 Q7L7X3 2/20 0.39
MINK1 Q8N4C8 2/20 0.39
HIPK4 Q8NE63 2/20 0.39
SRPK1 Q96SB4 2/20 0.39
HIPK2 Q9H2X6 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4175228 0.88 MCL1 (0.46) MCL1ALBSIRT2HTR1AHTR1D
SCHEMBL4164635 0.80 MCL1 (0.45) MCL1ALBSIRT2HTR1AHTR1D
SCHEMBL4163013 0.77 MCL1 (0.68) MCL1ALBCDC7MARK3GSK3B
SCHEMBL4165618 0.77 MCL1 (0.67) MCL1ALBCDC7MARK3GSK3B
SCHEMBL4154214 0.77 MCL1 (0.67) MCL1ALBCDC7MARK3GSK3B
SCHEMBL19178651 0.75 MCL1 (0.56) MCL1ALBCDC7MARK3GSK3B
SCHEMBL4154300 0.74 MCL1 (0.66) MCL1ALBCDC7MARK3GSK3B
SCHEMBL19178603 0.74 MCL1 (0.55) MCL1ALBCDC7MARK3GSK3B
SCHEMBL19180450 0.73 MCL1 (0.57) MCL1ALBCDC7MARK3GSK3B
SCHEMBL4171894 0.72 MCL1 (0.66) MCL1ALBCDC7MARK3GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3243814-B1 7-SUBSTITUTED INDOLE AS MCL-1 INHIBITORS ABBVIE INC (US) 2018-10-17 EP disclosed
EP-3243814-A1 7-SUBSTITUTED INDOLE AS MCL-1 INHIBITORS AbbVie Inc. (US) 2017-11-15 EP disclosed
EP-2134684-B1 7-SUBSTITUTED INDOLE AS MCL-1 INHIBITORS ABBVIE INC (US) 2017-08-02 EP disclosed
US-9359296-B2 7-substituted indole Mcl-1 inhibitors ABBVIE INC. (US) 2016-06-07 US disclosed
US-20150284328-A1 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS ABBVIE INC (US) 2015-10-08 US disclosed
US-9035047-B2 7-substituted indole Mcl-1 inhibitors ABBVIE INC. (US) 2015-05-19 US disclosed
US-20140051683-A1 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS ABBVIE INC. (US) 2014-02-20 US disclosed
US-8445679-B2 7-substituted indole MCL-1 inhibitors ABBVIE INC. (US) 2013-05-21 US disclosed
EP-2134684-A2 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS Abbott Laboratories (US) 2009-12-23 EP disclosed
US-20090054402-A1 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS ABBOTT LABORATORIES (US) 2009-02-26 US disclosed
WO-2008131000-A2 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS ABBOTT LABORATORIES (US) 2008-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140051683-A1 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS MCL1, BCL2L1, API5 MCL1 1/4885ALB 3819/4885SIRT2 2076/4885
US-20150284328-A1 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS MCL1, BCL2L1, API5 MCL1 1/4885ALB 3819/4885SIRT2 2076/4885
US-20090054402-A1 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS MCL1, BCL2L1, API5 MCL1 1/4885ALB 3819/4885SIRT2 2076/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.